NEW YORK (GenomeWeb) – Danaher today initiated its earning outlook for 2019, saying EPS is anticipated to be in the range of $4.02 to $4.12.
On a non-GAAP basis, EPS is expected to be in the range of $4.75 to $4.85, which assumes non-GAAP core revenue growth of about 4 percent. The Washington-based conglomerate, which owns Cepheid, Sciex, Beckman Coulter, and other life sciences and diagnostics companies, issued its guidance ahead of its annual investor and analyst meeting being held today.